


AMENDMENTS TO THE CLAIMS


Please amend the claims as follows:

1. (Currently Amended) An imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, an ester, a hydrate, a solvate or a salt thereof:



wherein

R¹ represents



in which

n represents an integer of 0 to 6;


Q₁ represents -NH-, -N(C₁₋₆ alkyl)-, or -O- ;

Y represents hydrogen, C₃₋₈ cycloalkyl optionally substituted by C₁₋₆ alkyl, C₃₋₈ cycloalkyl fused by benzene, aryl or heteroaryl, wherein said aryl and

heteroaryl are optionally substituted at a substitutable position with one or more substituents selected from the group consisting of cyano, halogen, nitro, guanidino, pyrrolyl, sulfamoyl, C₁₋₆ alkylaminosulfonyl, di(C₁₋₆ alkyl)aminosulfonyl, phenyloxy, phenyl, amino, C₁₋₆alkylamino, ~~di(C₁₋₆ alkyl)amino~~ di(C₁₋₆ alkyl)amino, C₁₋₆ alkoxy carbonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, di-(C₁₋₆ alkyl)carbamoyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri- halogen and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen, or aryl fused by 1,3-dioxolane;


R² represents hydrogen or C₁₋₆ alkyl;

R³ represents hydrogen, halogen, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri- halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri- halogen,



in which

R^{3a} and R^{3b} independently represent C₃₋₈ cycloalkyl, or C₁₋₆ alkyl optionally substituted by carboxy, C₃₋₈ cycloalkyl, carbamoyl, C₁₋₆ alkylcarbamoyl, aryl-substituted C₁₋₆ alkylcarbamoyl, C₁₋₆ alkylcarbamoyl, di(C₁₋₆ alkyl)carbamoyl, C₃₋₈ cycloalkylcarbamoyl, C₃₋₈ heterocyclocarbonyl, C₁₋₆ alkylamino, ~~di(C₁₋₆ alkyl)amino~~ di(C₁₋₆ alkyl)amino or C₁₋₆ alkoxy,



in which

q represents an integer of 1 to 3;

R^{3c} represents hydrogen, hydroxy, carboxy, or C_{1-6} alkyl optionally substituted by hydroxy, carboxy or (phenyl-substituted C_{1-6} alkyl)carbamoyl;

Xa represents -O-, -S- or -N(R^{3d})-

in which


R^{3d} represents hydrogen or C_{1-6} alkyl; and

R^4 represents hydrogen or C_{1-6} alkyl.

2. (Currently Amended) The imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, an ester, a hydrate, a solvate or a salt thereof as claimed in claim 1,

wherein

R^1 represents



in which

n represents an integer of 0 to 2;

Q_1 represents -NH-, -N(C_{1-6} alkyl)-, or -O- ;

Y represents C_{3-8} cycloalkyl optionally substituted by C_{1-6} alkyl, C_{3-8} cycloalkyl fused by benzene, aryl selected from the group consisting of phenyl and naphthyl, or heteroaryl selected from the group consisting of indolyl, quinolyl, benzofuranyl, furanyl and pyridyl, wherein said aryl and heteroaryl are optionally substituted at a substitutable position with one or more substituents selected from the group consisting of cyano, halogen, nitro, pyrrolyl, sulfamoyl, C_{1-6} alkylaminosulfonyl, di(C_{1-6} alkyl)aminosulfonyl, phenyloxy, phenyl, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkoxy carbonyl, C_{1-6} alkanoylamino, carbamoyl, C_{1-6} alkylcarbamoyl, di-(C_{1-6} alkyl)carbamoyl, C_{1-6} alkylsulfonyl, C_{1-6} alkyl optionally substituted by mono-, di-, or tri-halogen, C_{1-6} alkoxy optionally


substituted by mono-, di-, or tri- halogen and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen; and

R² represents hydrogen.

3. (Currently Amended) The imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, an ester, a hydrate, a solvate or a salt thereof as claimed in claim 1,


wherein

R³ represents hydrogen, halogen, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri- halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri- halogen,



in which

R^{3a} and R^{3b} independently represent C₁₋₆ alkyl optionally substituted by carboxy, C₃₋₈ cycloalkyl, carbamoyl, C₁₋₆ alkylcarbamoyl, di(C₁₋₆ alkyl)carbamoyl, C₃₋₈ cycloalkylcarbamoyl, C₃₋₈ heterocyclocarbonyl, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino or C₁₋₆ alkoxy,



in which


R^{3c} represents hydrogen, hydroxy, carboxy, or C₁₋₆ alkyl optionally substituted by hydroxy, carboxy or (phenyl-substituted C₁₋₆ alkyl)carbamoyl;

Xa represents -O-, -S- or -N(R^{3d})-,

in which


R^{3d} represents C₁₋₆ alkyl.

4. (Currently Amended) An imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I-i), its tautomeric or stereoisomeric form, an ester, a hydrate, a solvate or a salt thereof ;



wherein

R¹ represents



in which

n represents an integer of 0 to 2;

Q₁ represents -NH-, -N(C₁-₆ alkyl)-, or -O- ;


Y represents phenyl, naphthyl, indolyl, quinolyl, benzofuranyl, furanyl or pyridyl,

wherein said phenyl, naphthyl, indolyl, quinolyl, benzofuranyl, furanyl and pyridyl are optionally substituted at a substitutable position with one or two substituents selected from the group consisting of cyano, halogen,

nitro, phenyloxy, phenyl, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri-halogen and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri-halogen;


R² represents hydrogen or C₁₋₆ alkyl;

R³ represents hydrogen, halogen, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri-halogen, C₁₋₆ alkoxy,



in which

R^{3a} and R^{3b} independently represent C₃₋₈ cycloalkyl, or C₁₋₆ alkyl optionally substituted by C₃₋₈ cycloalkyl, carbamoyl, C₁₋₆ alkylcarbamoyl, (phenyl-substituted C₁₋₆ alkyl)carbamoyl, C₁₋₆ alkylcarbamoyl, di(C₁₋₆ alkyl)carbamoyl, C₃₋₈ cycloalkylcarbamoyl, C₃₋₈ heterocyclocarbonyl, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino or C₁₋₆ alkoxy,



R^{3c} represents hydrogen, hydroxy, carboxy, or C₁₋₆ alkyl optionally substituted by hydroxy, carboxy or (phenyl-substituted C₁₋₆ alkyl)carbamoyl; and

R⁴ represents hydrogen or methyl.

5. (Currently Amended) The imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, an ester, a hydrate, a solvate or a salt thereof as claimed in claim 1, wherein said imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I) is selected from the group consisting of:

[7-chloro-5-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)imidazo[1,2-c]pyrimidin-8-yl]acetic acid;

(7-chloro-5-{4-[(3,4-dichlorobenzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetic acid;

{7-chloro-5-[4-(2-naphthoylamino)benzyl]imidazo[1,2-c]pyrimidin-8-yl}acetic acid;

[7-chloro-5-(4-{[(2E)-3-phenylprop-2-enoyl]amino}benzyl)imidazo[1,2-c]pyrimidin-8-yl]acetic acid;

[7-chloro-5-(4-{[(2E)-3-(4-chlorophenyl)prop-2-enoyl]amino}benzyl)imidazo[1,2-c]pyrimidin-8-yl]acetic acid;

(5-{4-[(3,4-dichlorobenzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetic acid; and

[5-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)imidazo[1,2-c]pyrimidin-8-yl]acetic acid.

6. (Currently Amended) A pharmaceutical composition ~~medicament~~ comprising the imidazo[1,2-c]pyrimidinylacetic acid derivative, its tautomeric or stereoisomeric form, an ester, a hydrate, a solvate or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient.
7. (Currently Amended) The pharmaceutical composition ~~medicament~~ as claimed in claim 6, further comprising one or more pharmaceutically acceptable excipients.
8. (Currently Amended) The pharmaceutical composition ~~medicament~~ as claimed in claim 6, wherein said imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, an ester, a hydrate, a solvate or a physiologically acceptable salt thereof is a CRTH2 antagonist.
9. (Canceled).
10. (Canceled).
11. (Canceled).
12. (Currently Amended) A method for treating or preventing a disorder or disease associated with CRTH2 activity in humans and animals by administering to the humans and animals a CRTH2 antagonistically effective amount of ~~Use of a compound according to claim 1 for manufacturing a medicament for the treatment and/or prevention of a disorder or disease associated with CRTH2 activity.~~

13. (Currently Amended) A method ~~Process~~ for controlling a disorder or disease associated with CRTH2 activity in humans and animals by administering to the humans and animals ~~administration of~~ a CRTH2 antagonistically effective amount of a compound according to claim 1.
14. (New) The pharmaceutical composition as claimed in claim 7, wherein the excipient is selected from carriers, diluents, flavoring agents, sweeteners, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating materials.
15. (New) The pharmaceutical composition as claimed in claim 14, wherein the excipient is a carrier selected from lactose, starch, sucrose, glucose, sodium carbonate, mannitol, sorbitol, calcium carbonate, calcium phosphate, calcium sulfate and methyl cellulose.
16. (New) The pharmaceutical composition as claimed in claim 15, further comprising a tablet disintegrating agent selected from maize, starch, methyl cellulose, agar bentonite, xanthan gum and alginic acid.
17. (New) The pharmaceutical composition as claimed in claim 15, wherein the carrier is in a form selected from tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
18. (New) The pharmaceutical composition as claimed in claim 14, wherein the excipient is a binder selected from gelatin, natural sugars, beta-lactose, corn sweeteners, natural and synthetic gums, acacia, tragacanth, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
19. (New) The pharmaceutical composition as claimed in claim 14, wherein the excipient is a lubricant selected from magnesium stearate, sodium stearate, stearic acid, sodium oleate, sodium benzoate, sodium acetate, sodium chloride and talc.

20. (New) The pharmaceutical composition as claimed in claim 6, wherein the amount of the active ingredient is from about 1 to about 99 weight percent, based on the total weight of the pharmaceutical composition.
21. (New) A unit dosage form comprising the imidazo[1,2-c]pyrimidinylacetic acid derivative, its tautomeric or stereoisomeric form, an ester, a hydrate, a solvate or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient.
22. (New) The unit dosage form of claim 21, wherein the quantity of the active ingredient is from about 0.1 to about 1000 milligrams.
23. (New) The method of claim 12, wherein said disorder or disease is asthma, allergic rhinitis, atopic dermatitis or allergic conjunctivitis.
24. (New) The method of claim 12, wherein said disorder or disease is Churg-Strauss syndrome, sinusitis, basophilic leukemia, chronic urticaria or basophilic leukocytosis.
25. (New) The imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, an ester, a hydrate, a solvate or a salt thereof as claimed in claim 1, wherein the imidazo[1,2-c]pyrimidinylacetic acid derivative is an ester of formula (I).
26. (New) The imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, an ester, a hydrate, a solvate or a salt thereof as claimed in claim 1, wherein the ester is an alkyl ester.
27. (New) The imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, an ester, a hydrate, a solvate or a salt thereof as claimed in claim 1, wherein the alkyl of the alkyl ester is a linear or branched alkyl radical having 1 to 6 carbon atoms.